Clinical Trials Logo

Mantle Cell Lymphoma clinical trials

View clinical trials related to Mantle Cell Lymphoma.

Filter by:

NCT ID: NCT01739309 Completed - Clinical trials for Mantle Cell Lymphoma

Study of LY2835219 for Mantle Cell Lymphoma

Start date: March 20, 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to estimate the disease control rate with abemaciclib for relapsed or refractory mantle cell lymphoma.

NCT ID: NCT01737177 Completed - Clinical trials for Mantle Cell Lymphoma

Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL

R2-B
Start date: July 31, 2012
Phase: Phase 2
Study type: Interventional

This is a prospective, multicenter phase II trial designed to evaluate the safety and activity of the combination of Bendamustine, Lenalidomide and Rituximab (R2-B) in patients with first relapsed/refractory mantle cell lymphoma (MCL) and the efficacy and safety of a maintenance treatment with Lenalidomide for 18 months from the end of R2-B (from month 7 to 24) for those responding to the induction.

NCT ID: NCT01665768 Completed - Clinical trials for Mantle Cell Lymphoma

Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma

Start date: September 2012
Phase: Phase 2
Study type: Interventional

This research is being done to determine if combining an investigational drug called Everolimus with Rituximab can reduce the risk of your cancer from returning after high dose chemotherapy.

NCT ID: NCT01662050 Completed - Clinical trials for Mantle Cell Lymphoma

Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL

FIL-RBAC500
Start date: March 20, 2012
Phase: Phase 2
Study type: Interventional

A phase 2 study of standard R-BAC (rituximab 375 mg/m2, bendamustine 70 mg/m2, ara-c 800 mg/m2) has been recently ultimated at the Vicenza Hematology Department involving several regional centers on both untreated and previously treated patients with Mantle Cell Lymphoma (MCL). An interim analysis conducted on 30 patients showed that rituximab + bendamustine + ara-c combination had very good clinical activity, but a quite relevant hematological toxicity, especially in previously treated and older patients (Visco C, ICML 2011 Lugano Conference, Poster 236). Objectives: The primary objective is to determine the activity (complete remission rate according to Cheson 2007 criteria) and safety of age-adjusted Rituximab-Bendamustine-Cytarabine (RBAC500) regimen at the end of treatment in older untreated patients with MCL. The secondary objectives are to determine: - The rate of molecular response (characterized by labs of the FIL) - The progression-free survival (PFS) - The overall survival (OS) - The duration of responses (DOR) - The rate of patients that complete the expected treatment schedule (6 courses) - The rate of patients that are subject to dose reductions or delays

NCT ID: NCT01652144 Completed - Clinical trials for Mantle Cell Lymphoma

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma

Start date: September 14, 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effects a new drug AT7519M has on mantle cell lymphoma.

NCT ID: NCT01646021 Completed - Clinical trials for Mantle Cell Lymphoma

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Start date: December 10, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma who received at least 1 prior chemotherapy regimen.

NCT ID: NCT01599949 Completed - Clinical trials for Mantle Cell Lymphoma

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Start date: August 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of ibrutinib in patients with mantle cell lymphoma who received at least 1 prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy.

NCT ID: NCT01597778 Completed - Clinical trials for Mantle Cell Lymphoma

Double Cord Versus Haploidentical (BMT CTN 1101)

Start date: June 2012
Phase: Phase 3
Study type: Interventional

Hematopoietic cell transplants (HCT)are one treatment option for people with leukemia or lymphoma. Family members,unrelated donors or banked umbilical cordblood units with similar tissue type can be used for HCT. This study will compare the effectiveness of two new types of bone marrow transplants in people with leukemia or lymphoma: one that uses bone marrow donated from family members with only partially matched bone marrow; and, one that uses two partially matched cord blood units.

NCT ID: NCT01562977 Completed - Clinical trials for Mantle Cell Lymphoma

Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL

RGemOx
Start date: April 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine efficacy of rituximab, gemcitabine, oxaliplatin and dexametasone (R-GemOx) chemotherapy schedule.

NCT ID: NCT01504776 Completed - Clinical trials for Mantle Cell Lymphoma

Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)

BUS48T
Start date: April 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and clinical efficacy of the combination of panobinostat plus bortezomib.